Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varlitinib plus Gemcitabine and Cisplatin in Treatment-Naïve Advanced Biliary Tract Cancer
NCT02992340Phase 2Terminated
- Sponsor
- ASLAN Pharmaceuticals
- Start
- Dec 2016
- Primary completion
- Jun 2020
- Countries
- 3
01
Overview
A Phase 2 trial of varlitinib in biliary tract cancer (BTC), sponsored by ASLAN Pharmaceuticals. Started Dec 2016; status: terminated.
02
Drugs
varlitinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT02992340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02992340.